Condition
End Stage Renal Disease on Hemodialysis (Diagnosis)
Total Trials
2
Recruiting
0
Active
1
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
2 treatments under study, led by Sertraline Oral Antidepressant
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 25/100
Termination Rate
0.0%
0 terminated out of 2 trials
Success Rate
100.0%
+13.4% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
100%
1 of 1 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
2Total
Not Applicable (1)
Phase 1 (1)
Trial Status
Completed1
Active Not Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.6%
Based on 1 completed trials
Clinical Trials (2)
Showing 2 of 2 trials
NCT06840379Not ApplicableActive Not Recruiting
Effect of Sertraline on Inflammation in Hemodialysis Patients with Depression: a Randomized Controlled Trial
NCT03934736Phase 1CompletedPrimary
HEPLISAV-B® in Adults With End-Stage Renal Disease (ESRD) Undergoing Hemodialysis
Showing all 2 trials
Research Network
Common Treatments
- Sertraline Oral Antidepressant1
- Heplisavb1
Active Sponsors
- Dynavax Technologies Corporation1
- Nishtar Medical University1
Top Investigators
Dynavax Technologies Corporation
Lahore General Hospital, Lahore
Related Conditions
- Inflamation1
- Hemodialysis1